vs
Orthofix Medical Inc.（OFIX）与1ST SOURCE CORP（SRCE）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是1ST SOURCE CORP的1.9倍（$219.9M vs $113.1M），1ST SOURCE CORP净利率更高（35.3% vs -1.0%，领先36.3%），1ST SOURCE CORP同比增速更快（8.7% vs 2.0%），1ST SOURCE CORP自由现金流更多（$58.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.8%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
第一来源公司（1st Source Corporation）是总部位于美国印第安纳州南本德的金融服务企业，旗下运营第一来源银行，在印第安纳州和密歇根州拥有81家分支机构，其专业金融团队为飞机、卡车、工程设备提供融资服务，同时还通过第一来源保险板块提供各类保险产品及相关服务。
OFIX vs SRCE — 直观对比
营收规模更大
OFIX
是对方的1.9倍
$113.1M
营收增速更快
SRCE
高出6.8%
2.0%
净利率更高
SRCE
高出36.3%
-1.0%
自由现金流更多
SRCE
多$41.3M
$16.8M
两年增速更快
OFIX
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $113.1M |
| 净利润 | $-2.2M | $40.0M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 45.4% |
| 净利率 | -1.0% | 35.3% |
| 营收同比 | 2.0% | 8.7% |
| 净利润同比 | 92.4% | 6.5% |
| 每股收益（稀释后） | $-0.05 | $1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXSRCE
| Q1 26 | — | $113.1M | ||
| Q4 25 | $219.9M | $110.8M | ||
| Q3 25 | $205.6M | $110.7M | ||
| Q2 25 | $203.1M | $108.2M | ||
| Q1 25 | $193.6M | $104.0M | ||
| Q4 24 | $215.7M | $97.8M | ||
| Q3 24 | $196.6M | $97.9M | ||
| Q2 24 | $198.6M | $97.3M |
净利润OFIXSRCE
| Q1 26 | — | $40.0M | ||
| Q4 25 | $-2.2M | $41.1M | ||
| Q3 25 | $-22.8M | $42.3M | ||
| Q2 25 | $-14.1M | $37.3M | ||
| Q1 25 | $-53.1M | $37.5M | ||
| Q4 24 | $-29.1M | $31.4M | ||
| Q3 24 | $-27.4M | $34.9M | ||
| Q2 24 | $-33.4M | $36.8M |
毛利率OFIXSRCE
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXSRCE
| Q1 26 | — | 45.4% | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | -8.3% | 49.7% | ||
| Q2 25 | -7.9% | 44.5% | ||
| Q1 25 | -25.2% | 45.8% | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -9.6% | 46.3% | ||
| Q2 24 | -12.5% | 49.1% |
净利率OFIXSRCE
| Q1 26 | — | 35.3% | ||
| Q4 25 | -1.0% | 37.1% | ||
| Q3 25 | -11.1% | 38.2% | ||
| Q2 25 | -6.9% | 34.5% | ||
| Q1 25 | -27.4% | 36.1% | ||
| Q4 24 | -13.5% | 32.1% | ||
| Q3 24 | -13.9% | 35.7% | ||
| Q2 24 | -16.8% | 37.8% |
每股收益（稀释后）OFIXSRCE
| Q1 26 | — | $1.63 | ||
| Q4 25 | $-0.05 | $1.67 | ||
| Q3 25 | $-0.57 | $1.71 | ||
| Q2 25 | $-0.36 | $1.51 | ||
| Q1 25 | $-1.35 | $1.52 | ||
| Q4 24 | $-0.76 | $1.27 | ||
| Q3 24 | $-0.71 | $1.41 | ||
| Q2 24 | $-0.88 | $1.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.3B |
| 总资产 | $850.6M | $9.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXSRCE
| Q1 26 | — | — | ||
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — |
总债务OFIXSRCE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXSRCE
| Q1 26 | — | $1.3B | ||
| Q4 25 | $450.0M | $1.3B | ||
| Q3 25 | $442.5M | $1.2B | ||
| Q2 25 | $458.3M | $1.2B | ||
| Q1 25 | $458.3M | $1.2B | ||
| Q4 24 | $503.1M | $1.1B | ||
| Q3 24 | $525.9M | $1.1B | ||
| Q2 24 | $546.0M | $1.0B |
总资产OFIXSRCE
| Q1 26 | — | $9.1B | ||
| Q4 25 | $850.6M | $9.1B | ||
| Q3 25 | $832.6M | $9.1B | ||
| Q2 25 | $837.2M | $9.1B | ||
| Q1 25 | $823.1M | $9.0B | ||
| Q4 24 | $893.3M | $8.9B | ||
| Q3 24 | $867.9M | $8.8B | ||
| Q2 24 | $882.0M | $8.9B |
负债/权益比OFIXSRCE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $59.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $58.1M |
| 自由现金流率自由现金流/营收 | 7.6% | 51.4% |
| 资本支出强度资本支出/营收 | 4.9% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $361.4M |
8季度趋势，按日历期对齐
经营现金流OFIXSRCE
| Q1 26 | — | $59.1M | ||
| Q4 25 | $27.7M | $223.1M | ||
| Q3 25 | $12.4M | $51.0M | ||
| Q2 25 | $11.6M | $44.9M | ||
| Q1 25 | $-18.4M | $71.8M | ||
| Q4 24 | $23.7M | $193.9M | ||
| Q3 24 | $11.7M | $68.4M | ||
| Q2 24 | $9.0M | $50.0M |
自由现金流OFIXSRCE
| Q1 26 | — | $58.1M | ||
| Q4 25 | $16.8M | $213.0M | ||
| Q3 25 | $2.5M | $47.3M | ||
| Q2 25 | $4.5M | $43.0M | ||
| Q1 25 | $-25.1M | $69.3M | ||
| Q4 24 | $15.2M | $181.5M | ||
| Q3 24 | $6.3M | $66.7M | ||
| Q2 24 | $-360.0K | $46.4M |
自由现金流率OFIXSRCE
| Q1 26 | — | 51.4% | ||
| Q4 25 | 7.6% | 192.2% | ||
| Q3 25 | 1.2% | 42.7% | ||
| Q2 25 | 2.2% | 39.8% | ||
| Q1 25 | -13.0% | 66.6% | ||
| Q4 24 | 7.0% | 185.5% | ||
| Q3 24 | 3.2% | 68.1% | ||
| Q2 24 | -0.2% | 47.7% |
资本支出强度OFIXSRCE
| Q1 26 | — | 0.9% | ||
| Q4 25 | 4.9% | 9.1% | ||
| Q3 25 | 4.8% | 3.4% | ||
| Q2 25 | 3.5% | 1.7% | ||
| Q1 25 | 3.5% | 2.4% | ||
| Q4 24 | 4.0% | 12.6% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 4.7% | 3.7% |
现金转化率OFIXSRCE
| Q1 26 | — | 1.48× | ||
| Q4 25 | — | 5.42× | ||
| Q3 25 | — | 1.21× | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 1.91× | ||
| Q4 24 | — | 6.17× | ||
| Q3 24 | — | 1.96× | ||
| Q2 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SRCE
暂无分部数据
